Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations ...